Caribou Biosciences, Inc. (CRBU)
NASDAQ: CRBU · Real-Time Price · USD
1.805
-0.120 (-6.23%)
Jul 13, 2026, 10:53 AM EDT - Market open
Caribou Biosciences Revenue
Caribou Biosciences had revenue of $2.40M in the quarter ending March 31, 2026, with 1.87% growth. This brings the company's revenue in the last twelve months to $11.20M, up 12.96% year-over-year. In the year 2025, Caribou Biosciences had annual revenue of $11.16M with 11.66% growth.
Revenue (ttm)
$11.20M
Revenue Growth
+12.96%
P/S Ratio
17.04
Revenue / Employee
$115,495
Employees
97
Market Cap
179.02M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 11.16M | 1.17M | 11.66% |
| Dec 31, 2024 | 9.99M | -24.48M | -71.01% |
| Dec 31, 2023 | 34.48M | 20.63M | 148.91% |
| Dec 31, 2022 | 13.85M | 4.25M | 44.31% |
| Dec 31, 2021 | 9.60M | -2.76M | -22.35% |
| Dec 31, 2020 | 12.36M | 6.57M | 113.56% |
| Dec 31, 2019 | 5.79M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Protalix BioTherapeutics | 76.38M |
| Arcturus Therapeutics Holdings | 54.71M |
| Q32 Bio | 53.74M |
| MediWound | 14.48M |
| Alpha Cognition | 10.83M |
| Equillium | 4.39M |
| Humacyte | 2.02M |
| Outlook Therapeutics | 333.14K |
CRBU News
- 13 days ago - Caribou Biosciences Transcript: H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - Transcripts
- 14 days ago - Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - GlobeNewsWire
- 26 days ago - Caribou Biosciences Transcript: AGM 2026 - Transcripts
- 4 weeks ago - Caribou Biosciences presents ANTLER trial results at EHA - TheFly
- 4 weeks ago - Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026 - GlobeNewsWire
- 4 weeks ago - Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting - GlobeNewsWire
- 4 weeks ago - Caribou Biosciences Slides: Corporate presentation - Filings
- 5 weeks ago - Caribou Biosciences Proxy statement: Proxy filing - Filings